Today, about 6 million Americans are suffering from heart failure, which has become the leading cause of hospitalization for people over 65 years of age, with annual treatment costs exceeding $31 billion. Endotronix, a digital health medical technology company, is developing technologies that will enable early intervention and promise to dramatically improve patient care and significantly reduce the cost of the healthcare system.
On July 14, Endotronix announced the completion of a $32 million Series C financing, involving SV Life Sciences (SVLS), Lumira Capital, Aperture Venture Partners, OSF Ventures, existing investors and a corporate strategic investor. The financing will be used primarily to support the company's safety and feasibility studies for implantable wireless pulmonary sensors and to facilitate the commercialization of outpatient management systems.
Founded in 2007, Endotronix was founded by a mechanical engineer and a cardiothoracic surgeon. The company offers digital medical technology solutions that combine a cloud-based patient management system with an implantable pulmonary artery sensor to improve the status of outpatient hemodynamic management. This wireless solution seamlessly integrates key physiological data from routine clinical testing, enhancing communication between patients, caregivers and physicians, enabling early detection of heart failure symptoms and reducing hospitalization rates for heart failure patients. By monitoring lung pressure in real time, the company has reduced hospitalization rates for heart failure patients by 37%.
Endotronix is ​​currently developing a single platform for integrated medical device and patient management solutions that provide comprehensive, reimbursable health management for patients with acute heart failure. The company's end-to-end solutions for more than 23 million heart failure patients worldwide are designed to reduce hospitalization and hospital stays. Endotronix has received the Nokia Challenge Technology XCHALLENGE Competition Excellence Award, which recognizes breakthrough medical technology sensing technology developed worldwide, enabling faster diagnostic speeds and easier health monitoring behavior.
Leslie Saxo, a medical doctor and executive director of the Center for Body Computing at the University of Southern California, said in a press conference: "Patient-friendly wireless solutions provide early detection and promote long-term communication between patients and doctors. There is great potential for management of chronic heart failure. Currently, inefficient management and communication channels are a common concern for patients and doctors, and Endotronix's solutions will be able to optimize these issues."
Organic Intermediates
Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com